<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Jood Alnaqbi on Medium]]></title>
        <description><![CDATA[Stories by Jood Alnaqbi on Medium]]></description>
        <link>https://medium.com/@J.oo.d?source=rss-53dd1d99b48a------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*8cRwLsIW82x-sRhsWkP-SA@2x.jpeg</url>
            <title>Stories by Jood Alnaqbi on Medium</title>
            <link>https://medium.com/@J.oo.d?source=rss-53dd1d99b48a------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 17:11:02 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@J.oo.d/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Why Tomorrow’s Cure Might Never Reach You]]></title>
            <link>https://medium.com/@J.oo.d/why-tomorrows-cure-might-never-reach-you-7f22f400abc0?source=rss-53dd1d99b48a------2</link>
            <guid isPermaLink="false">https://medium.com/p/7f22f400abc0</guid>
            <category><![CDATA[regenerative-medicine]]></category>
            <category><![CDATA[stem-cell-therapy]]></category>
            <category><![CDATA[medical-manufacturing]]></category>
            <dc:creator><![CDATA[Jood Alnaqbi]]></dc:creator>
            <pubDate>Fri, 20 Nov 2026 16:34:24 GMT</pubDate>
            <atom:updated>2026-11-20T16:34:24.021Z</atom:updated>
            <content:encoded><![CDATA[<p><strong>The future of medicine may depend less on discovering new cures and more on learning how to manufacture them.</strong></p><h4>From Research Question to Prototype</h4><p>When I first started researching regenerative medicine, I expected to spend most of my time learning about stem cells, organoids, and bioprinting. Instead, I became fascinated by a completely different problem: manufacturing.</p><p>Throughout my research, I noticed that many regenerative medicine therapies were showing promising clinical results. Scientists were successfully reprogramming skin cells into induced pluripotent stem cells (iPSCs), differentiating them into specialized cell types, and transplanting them into patients. Companies such as Aspen Neuroscience and BlueRock Therapeutics were demonstrating that regenerative approaches could potentially replace damaged cells rather than simply managing symptoms.</p><p>However, I kept encountering the same challenge. Even when a therapy worked biologically, producing it was expensive, slow, and difficult to scale. The more I researched, the more I became convinced that manufacturing might be the biggest obstacle preventing regenerative medicine from becoming widely accessible.</p><p>That observation became the foundation for this project.</p><h4>Project Goal</h4><p>I wanted to create an interactive tool that would help users understand how manufacturing decisions affect the practicality of regenerative medicine therapies.</p><p>Rather than building another informational website, I decided to build an interactive model that allows users to explore the manufacturing process behind a cell therapy. My goal was not simply to explain regenerative medicine, but to make people think about the tradeoffs hidden behind every promising breakthrough.</p><p>Most people think about cures in terms of scientific discovery. I wanted people to think about what happens after the discovery.</p><h4>What I Built</h4><p>I created the Cell Therapy Simulator, an interactive web experience that explores what it takes to turn a patient’s cells into a treatment.</p><p>The simulator follows the same five-stage pipeline commonly discussed in regenerative medicine:</p><ul><li>Harvest skin cells</li><li>Reprogram cells into iPSCs</li><li>Differentiate cells into specialized tissue</li><li>Purify and test the cells</li><li>Implant the therapy</li></ul><p>Users can adjust the cost, production time, and success rate of each stage and immediately see how those decisions influence the final outcome.</p><p>Rather than presenting regenerative medicine as a purely biological process, the simulator treats it as a manufacturing challenge. Users can compare two different approaches: Personalized Batch Manufacturing, where therapies are produced specifically for one patient, and Automated Factory-Scale Manufacturing, where production is organized to serve many patients more efficiently.</p><p>The goal is to help users understand that creating a therapy is only part of the challenge. Producing it safely, efficiently, and affordably may be equally important.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/921/1*tGueTDPVRvkig6xONlCEzg@2x.jpeg" /><figcaption>Figure 1. Homepage of the Cell Therapy Simulator introducing the central question: what does it actually take to grow a medicine?</figcaption></figure><h4>How the Simulator Works</h4><p>While building the simulator, I wanted to avoid creating a simple cost calculator. Instead, I wanted the model to capture several of the tradeoffs that real regenerative medicine companies face.</p><p>The simulator calculates overall treatment success by combining the success rates of each manufacturing stage. This reflects the reality that every step introduces additional risk. Even if each stage performs reasonably well on its own, a long manufacturing process creates more opportunities for failure.</p><p>The model also estimates patient accessibility using manufacturing costs. Lower production costs lead to higher accessibility, while expensive treatments are classified as luxury therapies. This is obviously a simplification because real-world access depends on insurance systems, healthcare infrastructure, and government policy. However, it helps illustrate one of the major themes from my research: a therapy can work scientifically and still fail to reach most patients.</p><p>I also incorporated educational elements throughout the experience. Instead of expecting users to know technical terms such as differentiation or purification, each stage includes scientific context explaining what is happening and why it matters.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/594/1*Sy_n6xmcp6lJwWGj6mJqkA@2x.jpeg" /><figcaption>Figure 2. Interactive simulator showing the five manufacturing stages and the adjustable variables used throughout the model.</figcaption></figure><h4>The Development Process</h4><p>I built the project using HTML, CSS, and JavaScript before redesigning and rebuilding the final version using <strong>Base44</strong>.</p><p>The first version was simple. Users could modify success rates and view basic results. However, the more I worked on the project, the more I realized that numbers alone were not enough.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/374/1*ZTxv6lhivNa6FrBPywYS-g@2x.jpeg" /><figcaption>the original website you can check it out: <a href="https://jood-ie.github.io/codespaces-cell-therapy/">https://jood-ie.github.io/codespaces-cell-therapy/</a></figcaption></figure><p>My research was really about understanding why regenerative medicine is difficult to scale. Because of this, I redesigned the project around explanation as much as simulation. Using Base44, I created a guided interactive experience that walks users through the manufacturing process, compares different production strategies, and highlights the tradeoffs hidden within each decision.</p><p>As the project evolved, I added educational explanations, scientific context for each manufacturing stage, comparisons between personalized and factory-scale production, and a dedicated Insights section focused on accessibility, risk, and quality control.</p><p>Over time, the project became less of a calculator and more of an educational model. The goal shifted from simply displaying results to helping users understand why regenerative medicine manufacturing is such a difficult challenge in the first place.</p><h4>What This Project Replicates</h4><p>This simulator is a simplified digital representation of the manufacturing pipeline discussed throughout my regenerative medicine research.</p><p>Rather than replicating one company or one clinical trial, it combines ideas from several examples I encountered while researching iPSC therapies, personalized cell manufacturing, and regenerative medicine production systems.</p><p>The manufacturing stages are inspired by real regenerative medicine workflows, but the values used in the simulator are illustrative rather than clinical. The project is designed to help users understand manufacturing tradeoffs, not to predict actual clinical results.</p><p>That distinction became increasingly important as I built the project. My goal was not to model biology with perfect accuracy. My goal was to make an invisible system visible.</p><h4>Expanding the Simulator</h4><p>Originally, the simulator focused on manufacturing outcomes. As the project evolved, I realized that showing users the numbers was only half the problem.</p><p>People needed to understand what the numbers meant.</p><p>That realization led me to build the Insights section of the website.</p><p>Rather than simply displaying results, the simulator explains three ideas that repeatedly appeared throughout my research:</p><p>Cost decides access. Manufacturing often determines who can realistically receive a therapy.</p><p>Time compounds risk. Every additional week increases the chance that a batch will fail and adds cost to the process.</p><p>Quality is safety. Purification and testing are not optional expenses. They are critical safeguards designed to protect patients.</p><p>These insights transformed the project from a simulation into a learning experience.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/786/1*pukKX55XX8fm5paha6EjLA@2x.jpeg" /><figcaption>Figure 3. Insights section connecting manufacturing decisions to accessibility, risk, and patient safety.</figcaption></figure><h4>Challenges I Encountered</h4><p>The hardest part of the project was not the programming.</p><p>The hardest challenge was deciding how much complexity to include.</p><p>Real regenerative medicine manufacturing involves hundreds of variables, extensive quality control, regulatory oversight, and years of scientific development. Trying to represent all of that accurately would have produced a tool that was too complicated to be useful.</p><p>Instead, I had to simplify the system while preserving the central idea I wanted users to understand: every stage introduces cost, time, and risk.</p><p>Another challenge was translating ideas such as accessibility and patient access into something that users could interact with. Costs are easy to display. Access is not. Representing those tradeoffs in a meaningful way required a lot of experimentation.</p><p>Finally, I spent a surprisingly large amount of time improving the design. Building something functional is one challenge. Building something that feels intuitive and engaging is another.</p><h4>What I Learned</h4><p>This project taught me how to build interactive web applications using HTML, CSS, and JavaScript. It also taught me how to design user experiences, debug complex calculations, and communicate scientific concepts through visual tools.</p><p>More importantly, it changed how I think about regenerative medicine.</p><p>Before building the simulator, I mostly approached the field from a biological perspective. During development, I started thinking more like a manufacturer. Questions that initially seemed secondary became central.</p><ul><li>How much does production cost?</li><li>How long does manufacturing take?</li><li>Can therapies scale beyond a handful of patients?</li><li>What happens when a scientifically successful treatment remains economically inaccessible?</li></ul><p>Those questions pushed me to think beyond biology and into the broader systems that determine whether breakthroughs actually reach people.</p><h4>Comparing Personalized and Factory-Scale Manufacturing</h4><p>One of the most interesting parts of the simulator is the comparison between personalized and factory-scale manufacturing.</p><p>The two approaches run through the exact same biological pipeline. The difference is how production is organized.</p><p>In the personalized model, therapies are manufactured specifically for individual patients. In the factory-scale model, production becomes more standardized and efficient.</p><p>What surprised me most was that the biggest differences appeared in cost rather than biology. The manufacturing process remains largely the same, but the way it is organized dramatically changes accessibility.</p><p>This observation reinforced one of the central arguments from my research. Solving the scientific challenges is only part of the problem. Even a successful therapy can remain inaccessible if manufacturing remains expensive and difficult to scale.</p><p>The comparison helped me understand that manufacturing is not simply the final step in regenerative medicine. In many ways, it determines whether a breakthrough becomes widely available at all.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/741/1*Cfedzt2UQrUIhRJ8CZ-4TQ@2x.jpeg" /><figcaption>Figure 4. Comparison between Personalized Batch Manufacturing and Automated Factory-Scale Manufacturing.</figcaption></figure><h4>Reflection</h4><p>The biggest lesson from this project was realizing that scientific breakthroughs are only the beginning.</p><p>Developing a therapy is incredibly difficult. Making that therapy affordable and accessible at scale may be even harder.</p><p>My original research argued that regenerative medicine’s future may depend less on discovering new biology and more on improving manufacturing systems. Building this simulator allowed me to explore that idea in a hands-on way.</p><p>One feature I am particularly proud of is the Insights section. Most people think about regenerative medicine as a biological challenge. The Insights section allowed me to connect the science to manufacturing, accessibility, and safety. It helped transform the project from a simulator into something that teaches users how these systems interact.</p><p>The final product is not just a website. It is an attempt to visualize a question that emerged repeatedly throughout my research:</p><p><strong>If regenerative medicine can successfully regenerate damaged tissue, can we also learn to produce those therapies efficiently enough for everyone who needs them?</strong></p><blockquote>Website link: <a href="https://cell-flow-lab-app.base44.app/">https://cell-flow-lab-app.base44.app</a></blockquote><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7f22f400abc0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Body's Most Expensive Mistake]]></title>
            <link>https://medium.com/@J.oo.d/the-bodys-most-expensive-mistake-a27b3e056e61?source=rss-53dd1d99b48a------2</link>
            <guid isPermaLink="false">https://medium.com/p/a27b3e056e61</guid>
            <category><![CDATA[regenerative-medicine]]></category>
            <category><![CDATA[3d-bioprinting]]></category>
            <category><![CDATA[bioprinting]]></category>
            <dc:creator><![CDATA[Jood Alnaqbi]]></dc:creator>
            <pubDate>Sat, 24 Oct 2026 18:09:40 GMT</pubDate>
            <atom:updated>2026-11-19T09:09:03.872Z</atom:updated>
            <content:encoded><![CDATA[<h4>Why medicine’s greatest failure isn’t a disease, it’s the assumption that lost tissue can never come back.</h4><p>Every medical student is taught that brain cells, neurons, insulin-producing beta cells and the cardiac muscle never regenerate. Even though researchers acknowledge that, yet they are still trying to figure out a cure for those diseases, forcing modern medicine to rely instead on a century of brilliant compensation.</p><p>I came to this topic through animals, not people.</p><p>I&#39;ve spent years caring about how living systems heal. How a forest regrows after fire, how a wound closes, how a body knows what shape it&#39;s supposed to be. What bothered me was the exception: the tissues we&#39;d decided simply don&#39;t come back. Heart muscle. Neurons. The beta cells that make insulin. I kept wondering who decided that, and whether they were right.</p><p>Then in 2025, someone proved they might not be.</p><p>The question this article explores is simple: <strong>can regenerative medicine move from impressive early-stage breakthroughs to treatments that are safe, scalable, and accessible. Or will it remain a miracle that only a few can afford?</strong></p><h3><strong>The Assumption</strong></h3><p>The claim at the opening of this article. that heart muscle, neurons, and beta cells don’t come back is the assumption this whole field exists to test.I want to be careful here, because the absolute version of that claim is where medicine got comfortable, and comfort is exactly what made it worth questioning. The biology is more complex than &quot;never.&quot; Some neural circuits do remodel. The liver has a remarkable way of regrowing. But for the specific tissues that matter most in chronic disease, the practical reality has been loss without replacement.</p><p>Medicine built a century around that reality, and built it brilliantly. Beta-blockers for the scarred heart. Levodopa for the dying brain. Insulin injections for the empty pancreas.</p><p>All of it compensation rather than restoration: increasingly sophisticated ways to help a body cope with damage it can’t undo. The real prize was always teaching the body to undo it.</p><h3>How It Actually Works:</h3><p>Regenerative medicine is usually described as three things: stem cells, scaffolds, and bioprinting. but how does it actually work?</p><p>let&#39;s follow one real therapy from a patient&#39;s arm to a patient&#39;s brain.<strong>The therapy: ANPD001, from Aspen Neuroscience.</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/1*8dqriJGBHPgxxD5jBs9n-w@2x.jpeg" /><figcaption>Figure 1</figcaption></figure><p><strong>Step 1 — Harvest: </strong>A small patch of the patient’s skin is taken, usually from the arm. That sample contains ordinary skin cells (fibroblasts) which are not neurons and have no intention of becoming neurons.</p><p><strong>Step 2 — Reprogram:</strong> Those skin cells are treated with a set of factors that reset them to an earlier, unspecialized state. The result is an induced <a href="https://beikecelltherapy.com/blog/pluripotent-stem-cells/">pluripotent stem cell</a> induced , or iPSC: a cell rewound to something like an embryonic state, able to become many different cell types. This is the step that took science longest to figure out.</p><p><strong>Step 3 — Differentiate:</strong> The iPSCs are <a href="https://today.uic.edu/coaxing-single-stem-cells-into-specialized-cells/">coaxed</a>, over weeks, into becoming dopamine-producing neurons specifically. This happens through a carefully timed sequence of chemical signals that mimic what occurs in a developing embryo. Get the sequence wrong and you get the wrong cell type or worse, cells that never stop dividing.</p><p><strong>Step 4 — Purify and test:</strong> The batch is screened for purity. This matters more than it sound,: a single undifferentiated cell left in the mix could, in theory, form a tumor after transplantation. The batch is also checked for sterility and identity.</p><p><strong>Step 5 — Implant:</strong> The neurons are surgically delivered into the region of the brain where dopamine neurons have died.</p><p><strong>Step 6 — Observe:</strong> Then you wait. The cells must survive, integrate, and start producing dopamine, measured through motor function scores and imaging over months and years.</p><ul><li><strong>What goes in: </strong>a patch of skin.</li><li><strong>What happens:</strong> rewinding, redirecting, and screening cells over weeks of lab time.</li><li><strong>What comes out:</strong> a personalized dose of dopamine neurons, for one patient.</li></ul><p>What Aspen actually found: in May 2025, the company reported results from its Phase 1/2a trial showing improved motor function in three patients with a favorable safety profile. Three patients. That&#39;s a safety signal, not proof of efficacy, and it&#39;s important to say so plainly rather than let the number imply more than it does.</p><p>Here&#39;s what struck me. The elegance of this process is also its trap. Every step is designed around one person. Their cells, their batch, their clean room time. That&#39;s not a manufacturing flaw someone forgot to fix. It&#39;s the entire point of personalization. And it&#39;s why I don&#39;t think this particular therapy will ever be cheap, no matter how good the science gets. The moment I understood that, the rest of this article started organizing itself around a different question than the one I began with.</p><h3>The Trial That Changed the Assumption</h3><p>The breakthrough that changed everything wasn&#39;t a heart or a kidney. It was Parkinson&#39;s disease, the hardest possible test case.</p><p>For decades, Parkinson&#39;s was treated as effectively incurable. Dopamine-producing neurons in the brain die off, causing tremors, stiffness, and eventually severe disability. Because the medical community had no reliable way to replace those neurons, the disease was managed rather than reversed. That assumption went unchallenged for generations.</p><p>In 2025, that assumption was seriously tested for the first time. Two early-stage clinical trials, led by academic researchers, became the first to show that stem cell therapy could safely treat Parkinson&#39;s, reducing motor symptoms by replacing dying neurons with new ones grown in the lab. As Aitor Aguirre, chief of the Division of Developmental and Stem Cell Biology at Michigan State University, put it: &quot;We are witnessing the emergence of a new type of stem cell medicine that is well-substantiated and scientifically proven.&quot;</p><p>I want to be precise about what this actually proved, because the headlines blurred it. These were small, early-stage trials. They demonstrated safety and some improvement in motor function (not a cure), and not yet proof that the effect holds for everyone. What they did prove is more important than any single result: that the assumption itself, the one that said lost neurons are gone forever, may not hold.</p><p>And the companies racing to turn this into actual medicine are worth watching , though each one teaches us something different about where the field is succeeding and where it&#39;s still struggling.</p><h3>Three Companies, Three Lessons</h3><ul><li><a href="https://baptisthealth.net/services/brain-and-spine-care?gad_source=1&amp;gad_campaignid=21590756539&amp;gbraid=0AAAAAC7YN3R4cBnAjHTozLivOeJ8BMAaZ&amp;gclid=CjwKCAjw88HWBhA3EiwAo2Zd6OJOl9rP9UBA26wPZNrA5vsRTcIhPS07R070kpCZ19FxaswIPr-j5BoC-LsQAvD_BwE">Aspen Neuroscience:</a> founded by stem-cell biologist Jeanne Loring, is developing ANPD001, a personalized therapy made from each patient&#39;s own cells. In May 2025, it released results showing the therapy improved motor function in three patients with a good safety profile.</li></ul><p>What this example teaches: personalization works, but it&#39;s also the reason these therapies are so expensive. Making a treatment from one patient&#39;s own cells means you can never make it in bulk.</p><ul><li><a href="https://www.bluerocktx.com/">BlueRock Therapeutics:</a> now owned by Bayer, reported in October 2025 that its therapy bemdaneprocel improved motor symptoms with a favorable safety profile at 36 months. That&#39;s durability, not a flash in the pan.</li></ul><p>What this teaches: the question isn&#39;t just whether a therapy works, but whether it keeps working.</p><ul><li><a href="https://www.neuronatherapeutics.com/">Neurona Therapeutics:</a> showed that a one-time dose of its epilepsy therapy reduced seizures by 58–93% in some patients. A single injection, and seizures mostly gone.</li></ul><p>What this teaches: magnitude matters , but &quot;in some patients&quot; is doing a lot of work in that sentence.</p><p>What surprised me most wasn&#39;t the results themselves. It was how quickly a belief that had held for generations could be overturned in a single year. Parkinson&#39;s was always presented as the kind of disease you live with rather than recover from. That&#39;s the version most of us absorb, whether or not we ever sit in a medical classroom. Watching that framing flip made me realize how much of medicine rests on assumptions we&#39;ve simply stopped questioning, and how fast those assumptions can fall when the evidence finally arrives.</p><h4>The Quiet Revolution</h4><p>The neuron transplants captured the headlines, but the quieter revolution is happening in <strong>bioprinting</strong>. The technology now supports engineered cornea, cartilage, grafts, and organoids (miniature organs used for drug testing). And the potential here is massive. If we can print cartilage, we can <em>repair worn-out joints</em> without artificial replacements. If we can print corneas, we can <em>restore sight</em> to people waiting years for donor tissue. And if we can eventually print whole organs, we could <em>end the transplant waiting list entirely</em> . A list that kills thousands of people every year because there simply aren’t enough donors.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/360/1*Sm4k3EtURA1K-ifHTHp_bw@2x.jpeg" /><figcaption><a href="https://www.wired.com/2013/05/3-d-printed-ear-hears/">Figure 2- 3-D printed &quot;bionic&quot; ear. PHOTO: COURTESY FRANK WOJCIECHOWSKI</a></figcaption></figure><p>If I had to pick the breakthrough that matters most, it&#39;s this one, not because it&#39;s the flashiest, but because it&#39;s the one that could actually scale. Transplanting lab-grown neurons is remarkable, but it&#39;s still one patient, one procedure, one very expensive batch of cells. Printing tissue is a manufacturing process. And manufacturing is the only thing that has ever made a medical breakthrough reach everyone.</p><p>In addition, there’s an animal welfare angle here that matters to me personally too. <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/organoid">Organoids</a> could one day replace a significant share of animal testing. That’s a genuine win. But the same field also includes <a href="https://en.wikipedia.org/wiki/Xenotransplantation">xenotransplantation</a>, the idea of genetically engineering pigs to grow organs for humans, which raises hard ethical questions about how we treat animals in the name of saving people. A field that could reduce animal suffering in one direction while increasing it in another is part of why this topic matters so much to me. It’s not a clean story, and I don’t think it should be told as one.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/363/1*LSiH4UMOnLfCR03eOw41Yg@2x.jpeg" /><figcaption>Figure3-David Ayares, president and chief scientific officer of Revivicor, holds a piglet raised for research at a company farm in Montgomery County, Virginia. Scott P. Yates for NPR</figcaption></figure><h3>The Story That Shows Why This Matters</h3><p>The most ambitious version of this vision belongs to United Therapeutics, the company founded by Martine Rothblatt. Her story is the human heart of this field.</p><p>Rothblatt began her career in satellite radio, not medicine. She created SiriusXM. But in 1994, her seven-year-old daughter, Jenesis, was diagnosed with a rare and fatal lung disease called pulmonary hypertension. The drugs to treat it were unreliable, and her daughter&#39;s life hung in the balance. So Rothblatt did something extraordinary, she decided to make the drug herself. She founded United Therapeutics in 1996, and the company went on to develop the therapies that kept her daughter alive.</p><p>But she didn&#39;t stop there. Today, United Therapeutics is one of the leading companies working on organ manufacturing, using regenerative medicine to grow lungs, kidneys, and hearts for transplantation. The company&#39;s stated mission is nothing less than to end the organ shortage entirely.</p><p>Rothblatt&#39;s story changed how I think about this field. I used to assume the people driving regenerative medicine were pure scientists, motivated by curiosity. But the people pushing hardest ( Rothblatt, Jeanne Loring ) are often people who watched someone they love face a disease with no cure. That&#39;s not a clinical decision. That&#39;s a parent&#39;s decision. And I think that&#39;s why this field moves with such urgency compared to so much else in medicine.</p><h3>Where the Field Still Fails</h3><p>This is the part I care most about, because it&#39;s where the excitement has to survive contact with reality.</p><p><strong>Cost and accessibility:</strong> Personalized cell therapies require manufacturing a specific product for each patient, in clean rooms, with weeks of lab time. The global regenerative medicine market is projected to reach around $46–48 billion by 2026, but a market that size means nothing if the therapies reach only the wealthy. A breakthrough that only the rich can buy isn&#39;t a breakthrough. It&#39;s a luxury good with good press.</p><p><strong>The regulatory tightrope: </strong>For years, unregulated clinics sold unproven injections to desperate patients, sometimes causing blindness, tumors, or paralysis. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12994158/">The FDA eventually cracked down in court</a>, but the damage was done.</p><p>The real mistake wasn’t that regulators were slow. It was that they left an ambiguous space, and that space got filled by whoever profited from it. So when the FDA now permits faster approval paths, the risk isn’t approving something bad, it’s that &quot;faster&quot; gets read as &quot;less evidence needed.&quot;</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/385/1*VFTd6_JJQe1AZOqqTTdCXw@2x.jpeg" /><figcaption>Figure 4</figcaption></figure><p><strong>The manufacturing bottleneck: </strong>Growing neurons or <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/islet-cell">islet</a> cells that survive transplantation is extraordinarily hard. It requires precise control over differentiation, purity, and safety. One stray undifferentiated cell could become a tumor. Making these therapies reproducibly is still maturing, which is why most remain in early-stage trials rather than on pharmacy shelves.</p><p>Of these three, I&#39;d argue <em>manufacturing is the real bottleneck</em> because it sits upstream of the other two. If you can&#39;t make therapies reproducibly, you can&#39;t reduce cost, because every batch stays bespoke and risky. If you can&#39;t make them safely and consistently, regulators can&#39;t approve them faster, no matter how flexible the rules get. Cost and regulation are symptoms. Manufacturing is the disease.</p><h3>My Hypothesis</h3><ol><li>I believe regenerative medicine will do for the <strong>21st century what vaccines did for the 20th</strong>, and that the biggest winners won&#39;t be the disease-cure companies, but the ones that figure out how to make these therapies scalable and affordable. Here&#39;s my reasoning. Vaccines didn&#39;t transform public health because they were clever, they transformed it because they became <strong>cheap enough</strong> to give to everyone. Regenerative medicine is currently clever but expensive.</li></ol><ul><li>The company or country that cracks the manufacturing problem, that figures out how to produce personalized cell therapies at scale, will own the century&#39;s biggest medical market. And that&#39;s not just a business opportunity. It&#39;s the difference between a therapy that helps a few thousand wealthy patients and one that actually changes global health.</li></ul><p>I&#39;ll push this further, because I think it&#39;s the part people underestimate. The field&#39;s biggest obstacle isn&#39;t a scientific mystery, it&#39;s an industrial one. We already know these therapies can work. What we don&#39;t know is how to make them cheap, consistent, and fast enough to matter. That&#39;s a problem of process, not of biology. And history suggests process problems get solved by whoever decides to treat medicine like a manufacturing challenge rather than a research project.</p><p><strong>2. My second hot take: </strong>the organ shortage will end within our lifetimes. Not because we get more donors, but because we <strong>stop</strong> <strong>needing</strong> them. Between bioprinting, organ manufacturing, and xenotransplantation, the direction is clear. When that day comes, waiting for an organ will feel like something from the past, the way bloodletting does today. We’re not there yet. But the pieces are all moving in the same direction, and faster every year.</p><p>Where I think the field should go next: stop treating manufacturing as the unglamorous part that comes after the science. Fund it like it&#39;s the science. The labs that get the headlines and the labs that figure out how to make a million consistent batches are currently two different communities, and the second one is underfunded relative to how much of the outcome it determines.</p><h4>About Me</h4><p>I&#39;m a student passionate about biology and animal welfare. I&#39;m fascinated by how living systems. From forests to human cells, heal themselves when given the right support. Regenerative medicine sits at the intersection of everything I care about: biology, animals, and the belief that science can rebuild what disease tears down.</p><h3>Sources</h3><h4>Every claim above is supported by the resources below:</h4><ul><li><strong>Aspen Neuroscience / ANPD001</strong> —https://aspenneuroscience.com/</li><li><strong>BlueRock Therapeutics / bemdaneprocel </strong>— https://www.bluerocktx.com/</li><li><strong>Neurona Therapeutics</strong> —https://www.neuronatherapeutics.com/</li><li><strong>United Therapeutics / Martine Rothblatt</strong> — https://www.unither.com/about-us/leadership/martine-rothblatt</li><li><strong>Market projection ($46–48B by 2026)</strong> —https://www.grandviewresearch.com/industry-analysis/regenerative-medicine-market</li><li><strong>FDA September 2025 guidance</strong> —https://www.fda.gov/regulatory-information</li><li><strong>Tissue engineering overview</strong> —https://pmc.ncbi.nlm.nih.gov/articles/PMC3214857/</li><li><strong>Organ shortage data </strong>— https://www.organdonor.gov/learn/organ-donation-statistics</li><li><strong>TKS Life explore page</strong> — https://tks.life/explore/regenerative-medicine</li><li><strong>islet cell</strong>-<a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/islet-cell">NCI Dictionary of Cancer Terms</a></li><li><strong>Pluripotent stem cells for regenerative medicine</strong>-https://beikecelltherapy.com/blog/pluripotent-stem-cells/</li><li><strong>Figure3</strong>-https://www.opb.org/article/2024/02/29/how-genetically-modified-pigs-could-end-the-shortage-of-organs-for-transplants/</li><li><strong>Figure4</strong>-<a href="https://yourhealthmagazine.net/article/health-technology/the-significance-of-selecting-qualified-stem-cell-experts-in-treatment/">The Significance of Selecting Qualified Stem Cell Experts in Treatment</a></li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a27b3e056e61" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>